To The Moon

$Nexalin Technology, Inc.(NXL)$ $Neuronetics Inc.(STIM)$ $Eli Lilly(LLY)$ I’m fully convinced that what we’re seeing with $NXL right now is far more than a random bounce. The combination of clinical milestones, regulatory expansion, and technical positioning against a backdrop of historic volume shifts is exactly the type of asymmetric setup I want to dissect.

📅 Catalyst Front and Centre: September 9 Investor Webinar

Nexalin Technology has just confirmed a live investor webinar on September 9, 2025, with CEO Mark White presenting. This is not a typical IR event; it comes at a pivotal time when the company is showcasing its Deep Intracranial Frequency Stimulation (DIFS™) tech and Gen-3 HALO™ Clarity headset. I’m watching closely because FDA engagement and U.S. expansion strategy will be front and centre.

I’m confident that management’s tone here could reset the narrative, especially with investors hungry for disruptive healthcare plays that don’t rely on pharmaceuticals.

🧪 Breakthrough Technology Meets a $537B Market

Nexalin’s non-invasive neurostimulation is tackling depression, PTSD, substance use disorders, and even systemic issues like hypertension. Clinical data backs this: 29+ trials and peer-reviewed research point to measurable outcomes. The strategy is amplified by their Virtual Clinic model, integrating AI for at-home delivery.

I’m unequivocally optimistic about this because it positions $NXL to scale commercially while tapping into the global mental health crisis; an addressable market estimated at $537B.

🚨 Mental Health Crisis 🚨 Young people in Western countries are facing a sharp decline in mental well-being 😱

🌍 Bright spots: Central Africa, Southeast Asia, parts of Latin America, and Eastern Europe report the strongest mental health.

The UK population now has the lowest ranked mental wellbeing score in the world - and nearly 40% of the population are distressed/struggling.

Ultra-processed food consumption is associated with poor mental health.

This study of almost 300K people from around the world. 

🌍 Global Traction and Strategic Positioning

Regulatory approvals already span China, Brazil, and Oman, with CE Marking in progress. Trials with UC San Diego are targeting veterans with PTSD and TBI. Importantly, $NXL is serving as Industry Co-Chair of the National TBI Registry Coalition, cementing its credibility in the neurohealth ecosystem.

I’m tactically positioned to see these partnerships and validations not just as optional catalysts but as durable moats. This isn’t hype; it’s execution aligned with clinical and commercial credibility.

📈 Technical Setup and Volume Shift

The charts tell a story of long decline but an inflection is visible:

• Price: $0.8612 (up +3.26%).

• Structure: Trying to base between $0.90–$0.95. If this holds, I’m targeting a move toward $2+, with breakout extensions possible.

• Volume: Highest day in months, not explained by retail churn; institutions are stepping in.

On the daily and 4H charts, price is pushing against EMA compression with Bollinger/Keltner overlap. The micro timeframes show basing behaviour. I’m confident that buyers returning with this kind of volume spark is not noise; it’s the early pulse of a structure shift.

📊 Analyst Targets and Valuation Delta

One analyst has a $4 price target, implying +363.98% upside from current levels. The recommendation is a straight Buy, with no Hold or Sell positioning.

I’m deeply focused on this divergence: when sentiment has washed out yet analyst targets imply a 4x upside, it’s exactly the type of setup that benefits from asymmetry.

📊 Analyst Upside Comparison: NXL vs STIM

I’m highlighting how the Street’s upside on Nexalin dwarfs a credible peer. I’m confident that a clean comparison cuts through noise and foregrounds the asymmetry that matters to traders who screen for mispriced catalysts.

For NXL, the average 12-month target sits at $4.00 which implies roughly +365% from ~$0.86. For Neuronetics ($STIM), a neurostimulation peer, the average target is $7.00 which implies roughly +120% from ~$3.19. This comparison is unambiguous, and it pairs well with the volume-shift narrative and the September 9 webinar as the near-dated communication catalyst.

🔥 Short Interest as a Powder Keg

Short data highlights an opportunity:

• Short interest: 9.29M shares.

• Short ratio: 8.21%.

• Daily short volume: 196.7K.

I’m watching this because short covering on high volume spikes could act as an accelerant. The open short interest dropped to 37.7K (semi-monthly update), showing positioning is vulnerable. I’m confident that any positive narrative shift in September could force shorts to unwind quickly.

🔍 Technical Analysis Snapshot

• Short-term: Volatile decline trend, but stabilising.

• Medium/Long-term: Big rebound appears possible within the broader decline.

• Support: Key $0.90–$0.95 test zone.

• Pressure: A clean break over $1.20 would clear supply and validate a higher trend.

I’m watching these levels as execution checkpoints rather than arbitrary lines.

🧭 Investment Framework

This is not simply a trade; it’s a roadmap of how sentiment, clinical execution, and regulatory validation intersect. Nexalin is a microcap with binary risks, but it’s also an innovator in an underserved space. If FDA traction and commercial rollout are achieved, this could be a multi-bagger from oversold lows.

I’m here for the clinical milestones, the asymmetric reward profile, and the technical base-building that’s emerging.

💡 Final Conviction

This isn’t just a bounce; it’s a narrative inflection. $NXL is moving from being a forgotten microcap to a company that could force a revaluation once the market digests its September catalysts.

I’m extremely confident that this is the type of name where risk and opportunity collide.

Do you see the $0.90–$0.95 zone as the base for a larger cycle, or is this just another failed setup waiting to happen?

📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀

Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀

@Tiger_comments @TigerPicks @TigerStars @TigerPM @TigerWire @TigerObserver @Daily_Discussion